We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
+4.23%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$2.4B
AUM Growth
+$2.4B
Cap. Flow
+$169M
Cap. Flow %
7.05%
Top 10 Hldgs %
44.25%
Holding
367
New
126
Increased
77
Reduced
66
Closed
85

Top Buys

Rank Stock Value
1
TPST icon
Tempest Therapeutics
TPST
+$94.4M
2
IWM icon
iShares Russell 2000 ETF
IWM
+$24M
3
AGN
Allergan plc
AGN
+$13.8M
4
ZGNX
Zogenix, Inc.
ZGNX
+$11.9M
5
MBLY
Mobileye N.V.
MBLY
+$8.8M

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$42.1M
2
GILD icon
Gilead Sciences
GILD
+$11.5M
3
ACHN
Achillion Pharmaceuticals
ACHN
+$11.1M
4
A icon
Agilent Technologies
A
+$6.68M
5
ADVM
Adverum Biotechnologies
ADVM
+$3.71M

Sector Composition

Rank Sector Weight
1 Healthcare 9.36%
2 Technology 0.55%
3 Energy 0.39%
4 Industrials 0.16%
5 Financials 0.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GEVO icon
301
Gevo
GEVO
$363M
– –
-313
Closed -$601
GILD icon
302
Gilead Sciences
GILD
$167B
– –
-113,260
Closed -$11.5M
HRTX icon
303
Heron Therapeutics
HRTX
$92M
– –
-162,900
Closed -$1.84M
INCY icon
304
Incyte
INCY
$26B
– –
-10,564
Closed -$873K
ITP icon
305
IT Tech Packaging
ITP
$2.92M
– –
-23,880
Closed -$265
KEYS icon
306
Keysight
KEYS
$52.2B
– –
-83,978
Closed -$2.84K
LRMR icon
307
Larimar Therapeutics
LRMR
$398M
– –
-9,272
Closed -$3.43K
NKTR icon
308
CALL
Nektar Therapeutics
NKTR
$2.39B
– –
-159
Closed -$3.69K
OCUL icon
309
Ocular Therapeutix
OCUL
$1.85B
– –
-98,951
Closed -$2.33K
OPK icon
310
CALL
Opko Health
OPK
$1.23B
– –
-21,847
Closed -$21.8K
PFE icon
311
Pfizer
PFE
$144B
– –
-1,322,658
Closed -$42.1M
PGEN icon
312
CALL
Precigen
PGEN
$1.97B
– –
-1,046
Closed -$2.75K
PSTV icon
313
Plus Therapeutics
PSTV
$25.9M
– –
-1
Closed -$2.19M
RMTI icon
314
Rockwell Medical
RMTI
$27.6M
– –
-2,500
Closed -$2.93M
RMTI icon
315
PUT
Rockwell Medical
RMTI
$27.6M
– –
-47
Closed -$5.36K
SMLR
316
DELISTED
Semler Scientific
SMLR
– –
-115,423
Closed -$226
SVRA icon
317
Savara
SVRA
$1.09B
– –
-50,568
Closed -$1.98K
UTHR icon
318
CALL
United Therapeutics
UTHR
$26.1B
– –
-1,981
Closed -$25.7K
VRTX icon
319
PUT
Vertex Pharmaceuticals
VRTX
$124B
– –
-9,592
Closed -$114K
XOMA
320
DELISTED
Xoma
XOMA
– –
-25,087
Closed -$1.84M
XOMA
321
PUT
DELISTED
Xoma
XOMA
– –
-71
Closed -$512
CDMO
322
DELISTED
Avid Bioservices, Inc. Common Stock
CDMO
– –
-33,971
Closed -$5.2K
SGEN
323
CALL
DELISTED
Seagen Inc. Common Stock
SGEN
– –
-211
Closed -$678
SGEN
324
DELISTED
Seagen Inc. Common Stock
SGEN
– –
-17,378
Closed -$558
SGEN
325
PUT
DELISTED
Seagen Inc. Common Stock
SGEN
– –
-176
Closed -$565
11 12
13
14 15

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q1 2015 Portfolio in Review

As of Q1 2015, Sabby Management held 367 positions worth $2.4B, up 75,773% from $3.17M the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Sabby Management deployed $169M of net new capital in Q1 2015, opening 126 new positions and adding to 77 existing holdings. Its largest new stake was Tempest Therapeutics: 709 shares worth $4.69M.

By sector, the portfolio is most concentrated in Healthcare at 9.4% of assets, up from 9.2% a quarter earlier, followed by Technology and Energy.

On the sell side, the largest reduction was Achillion Pharmaceuticals, an estimated $11.1M trimmed.

  • Sabby Management's largest Q1 2015 buy was Tempest Therapeutics: 709 shares worth $4.69M.
  • Sabby Management added most to Allergan plc in Q1 2015, an estimated $13.8M increase.
  • Sabby Management's biggest Q1 2015 reduction was Achillion Pharmaceuticals, cutting an estimated $11.1M.
  • Sabby Management fully exited Pfizer in Q1 2015, selling an estimated $42.1M.
  • Sabby Management's ten largest holdings make up 44% of its $2.4B portfolio in Q1 2015.
  • Sabby Management opened 126 new positions and closed 85 in Q1 2015.
  • Sabby Management's portfolio value rose 75,773% quarter-over-quarter to $2.4B.

Based on Sabby Management's 13F filing for Q1 2015, filed 15 May 2015.